The Cancer Cachexia Action Network presents a seminar by:

Dr. Christopher M. Adams

Investigating Mechanisms and Treatment of Skeletal Muscle Atrophy

Abstract: My talk will discuss the research in my laboratory to discover and characterize novel stress-induced signaling mechanisms within skeletal muscle fibers that promote muscle atrophy and weakness during conditions such as aging, starvation, and immobilization. The talk will also discuss the work we are doing to discover and translate novel small molecule approaches for muscle atrophy and weakness.

Date: Friday, June 2, 2023
Time: 8:00 a.m.-10:00 a.m. (ET)

For a meeting invite please email: Sean Parnell at srp87@cinj.rutgers.edu

Dr. Adams completed his MD/Ph.D. in Physiology & Biophysics from the University of Iowa in 1999. Shortly after, Dr. Adams went on to the University of Texas Southwestern Medical Center where he completed his residency and post-doctoral fellowship in Endocrinology and metabolism in 2005. Dr. Adams then moved on to the University of Iowa from 2006-2021, where after 16 years, he became a tenured Professor of Medicine. Currently, Dr. Adams is a Professor of Medicine and Research Chair of the Division of Endocrinology, Diabetes, Metabolism and Nutrition at Mayo Clinic. Dr. Adams is also the founder and CEO of Emmyon, Inc.; a biotechnology company focused on small molecules for the prevention and treatment of skeletal muscle atrophy and related metabolic disorders. His clinical practice focuses on the care of patients with diabetes and other endocrine disorders. His research focuses on molecular mechanisms and the treatment of skeletal muscle atrophy and diabetes. Dr. Adams is the lead inventor on over 30 patents concerning small molecules that help maintain the structure and function of skeletal muscle. He leads a biotechnology company that is translating this research in collaboration with global companies and his laboratory at Mayo Clinic.